Plain-English translation of NCT05128825 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a new medication called for people with advanced ovarian, fallopian tube, or primary peritoneal cancer that no longer responds to platinum-based chemotherapy. The medication works by allowing cancer cells to accumulate too much DNA damage, which ultimately kills them. Researchers hope this treatment may help patients who have limited options after previous therapies have stopped working.
People with platinum-resistant ovarian cancer have very few treatment options and often face poor outcomes. This trial exists because the medication being tested uses a new approach to fight cancer cells, and early research suggests it may be effective for patients whose cancers have become resistant to standard treatments.
You likely qualify if…
You likely don't qualify if…
You would take the medication by mouth once daily for five days, then take two days off, and repeat this schedule. You would visit the clinic regularly so doctors can check how well the medication is working and monitor you for side effects through blood tests and scans. The trial involves multiple study arms and different doses, so your specific schedule and dose would depend on which part of the trial you join and your medical history.
AI-generated summary from trial data · Jul 8, 2026 · Not medical advice
United States